Table 3.

Effect size of text-based clinical updates

CME ACTIVITY	Participants			Non-participants			Effect size
	N	Mean % evidence-based response	SD	N	Mean % evidence-based response	SD
Psychiatry
Identifying patients with prodromal schizophrenia	35	73	12	28	49	16	1.76
Treatment nonadherence among individuals with schizophrenia	52	71	17	47	54	21	0.90
Treatment resistant schizophrenia	50	77	18	50	60	15	1.08
Reducing suicide risk in patients with schizophrenia	49	81	21	46	59	27	0.92
Recognizing and preventing abuse of rapid-onset opioids	50	68	21	57	48	21	0.93
Detecting autism in a toddler	100	68	19	102	50	22	0.85
Hyperactivity or autism	101	61	19	95	47	20	0.73
Infectious disease
Maximizing therapeutic success in an era of increasing antibiotic resistance	43	73	27	43	51	28	0.80
The role of antibiotics in serious hospital acquired infections	47	87	20	54	71	19	0.82
Fungal infection in the immunocompromised patient	47	68	21	39	54	21	0.65
Urology
Prostate cancer	26	71	24	28	49	19	0.28
Lower urinary tract symptoms in men	24	74	23	24	58	20	0.77
Evaluation and treatment of overactive bladder	41	74	29	45	63	28	0.37
Erectile dysfunction and cardiovascular disease	29	63	14	25	57	22	0.32
Cardiology
Statin efficacy and prevention of recurrent stroke	22	83	11	22	60	16	1.62
Diabetes, Metabolic Syndrome and very low cholesterol	59	88	21	59	72	30	0.62
Statins in the treatment of heart failure	50	60	18	49	45	19	0.83
Advances in hypertension	22	82	18	22	58	27	1.04
Medical adherence	22	55	22	22	38	16	0.89
Analysis of latest trial data points to new guidelines & restructured hypertension therapy	50	85	19	49	59	25	1.04
Neurology
The role of MRI in multiple sclerosis diagnosis and management	53	64	21	53	46	19	0.89
Breakthrough pain	73	75	27	73	48	29	0.98
Rheumatology
Risks and benefits of COX-2 selective inhibitors	85	70	23	98	62	24	0.36
Women's health
Contraception today	18	79	21	21	57	20	1.12